Lingyi Biotech Co., Ltd.
Clinical trials sponsored by Lingyi Biotech Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- One-Time gene therapy could change gaucher treatment forever Results expected Jul 2027 (estimated)
-
One-Time brain injection targets genetic form of Parkinson's
Disease control Not yet recruitingThis early-stage trial tests a single injection of a gene therapy called LY-N001, given directly into the brain fluid of people aged 30 to 70 with moderate-to-advanced Parkinson's disease who carry a GBA1 gene mutation. The main goal is to check safety and side effects, but resea…
Early phase 1 • Sponsor: Lingyi Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Gene therapy could free Wilson's patients from daily pills
Disease control Not yet recruitingThis early-stage trial tests a single-dose gene therapy called LY-M003 in 18 adults with Wilson's disease, a genetic condition that causes copper buildup. The goal is to see if it's safe and can reduce or eliminate the need for standard daily medications. Participants receive one…
Phase 1/2 • Sponsor: Lingyi Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC